US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0638-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0637-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0636-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0635-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0634-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0633-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0632-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0631-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0630-2025
Class II · Moderate risk Ongoing

Viorele

Reason Failed Impurities/Degradation Specifications

Glenmark Pharmaceuticals Inc., USA NDC 68462-318-29 D-0021-2026
Class II · Moderate risk Ongoing

Sulfamethoxazole and Trimethoprim

Reason Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 55154-7895-0 D-0625-2025
Class II · Moderate risk Ongoing

Sulfamethoxazole and Trimethoprim

Reason Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-2725-61 D-0624-2025
Class II · Moderate risk Ongoing

bevacizumab

Reason Lack of Assurance of Sterility

Fagron Compounding Services D-0646-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-034-01 D-0673-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-032-01 D-0672-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-031-01 D-0671-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-030-01 D-0670-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-029-01 D-0669-2025
Class II · Moderate risk Ongoing

Aripiprazole Tablets

Reason Superpotent drug

Ascend Laboratories, LLC D-0645-2025
Class I · High risk Ongoing

Green Lumber Natural Fuel For Men capsule

Reason Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil

Green Lumber Holdings, LLC D-0304-2026
Class I · High risk Ongoing

Cyclobenzaprine Hydrochloride Tablets

Reason Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).

Unichem Pharmaceuticals USA Inc. NDC 29300-415-19 D-0655-2025
Class II · Moderate risk Ongoing

chlorproMAZINE Hydrochloride Tablets

Reason Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Amerisource Health Services LLC D-0650-2025
Class II · Moderate risk Ongoing

chlorproMAZINE Hydrochloride Tablets

Reason Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Amerisource Health Services LLC D-0649-2025
Class II · Moderate risk Ongoing

chlorproMAZINE Hydrochloride Tablets

Reason Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Amerisource Health Services LLC D-0648-2025